Other Targets

Cat. No.

AT0404

AMG-305

AMG 305 represents an innovative dual-targeting BiTE (bispecific T-cell engager) molecule, specifically engineered with a half-life extended (HLE) format. This molecule uniquely targets both P-cadherin (CDH3) and mesothelin (MSLN) on tumor cells, in addition to CD3 on T-cells. The design of AMG 305 aims to enhance the therapeutic index in solid tumors by selectively engaging T-cells to tumor cells that co-express CDH3 and MSLN, while minimizing interaction with normal cells that express only one of these antigens. This selective mechanism of action positions AMG 305 as a promising candidate for targeted cancer therapy, especially in settings where both CDH3 and MSLN are overexpressed.

Cat. No.

AT0408

Anti-DC-SIGN/CD209 Antibody

The Anti-DC-SIGN/CD209 Antibody is a humanized antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target DC-SIGN/CD209. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of approximately 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is ideal for researchers focusing on cellular signaling, immune response modulation, and pathogen recognition studies involving DC-SIGN/CD209.

Cat. No.

AT0409

CAS No.

2414559-57-0

Ucenprubart

Ucenprubart is a human IgG4κ monoclonal antibody targeting CD200R1. For optimal experimental control, it is recommended to use Human IgG4 kappa as an isotype control.

Cat. No.

AT0410

CAS No.

127757-92-0

Maslimomab

Maslimomab is a murine-derived monoclonal antibody specifically designed to target the T-cell receptor. This antibody functions as an immunosuppressive agent, making it a valuable tool for research into T-cell mediated immune responses and potential therapeutic applications in immune-related disorders.

Cat. No.

AT0413

CAS No.

2329669-78-3

Bavunalimab

Synonyms: Anti-Human CTLA4xLAG3

Bavunalimab is a bispecific monoclonal antibody targeting CTLA-4 and LAG-3, designed for the dual inhibition of these immune checkpoint inhibitors. This humanized antibody promotes T-cell activation, demonstrated in NSG mouse models, making it a valuable tool for investigating immune responses in oncology research. Bavunalimab is specifically developed for studies focusing on the modulation of immune checkpoints in cancer therapy.

Cat. No.

AT0424

CAS No.

216669-97-5

Sibrotuzumab

Synonyms: BIBH 1; Anti-Human FAP Recombinant Antibody

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody that specifically targets the fibroblast activation protein (FAP). This antibody is utilized in research focusing on colorectal cancer and non-small cell lung cancer (NSCLC), providing a valuable tool for investigating the role of FAP in tumor progression and response to therapy.

Cat. No.

AT0428

CAS No.

2769937-42-8

Izastobart

Izastobart is a human IgG1 λ2 monoclonal antibody targeting C5AR1. For accurate experimental controls, it is recommended to use Human IgG1 lambda2 as an isotype control.

Cat. No.

AT0433

Anti-CHI3L1 Antibody

The Anti-CHI3L1 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CHI3L1. This antibody is comprised of a human IgG1 type heavy chain and a human kappa-type light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended as the isotype control for this antibody. This product is essential for researchers focusing on the biological pathways and disease associations involving CHI3L1.

Cat. No.

AT0435

CAS No.

2642173-04-2

Vipalanebart

Vipalanebart is a human IgG4 κ monoclonal antibody targeting ADCYAP1R. For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody provides a valuable tool for the specific detection and characterization of ADCYAP1R in various research applications.

Cat. No.

AT0444

CAS No.

2642374-04-5

Patecibart

Synonyms: Getagozumab; GMA-301

Patecibart is a humanized IgG4-kappa monoclonal antibody designed to specifically target and inhibit the endothelin receptor type A (EDNRA). As an endothelin receptor antagonist, it plays a critical role in modulating vascular function by blocking the binding of endothelin-1 to its receptor, potentially alleviating conditions associated with vascular dysfunction and constriction. This antibody is pivotal for research focused on cardiovascular diseases, pulmonary arterial hypertension, and other endothelin-related pathologies.

Cat. No.

AT0448

PF-07062119

PF-07062119 is a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to specifically target and inhibit guanylate cyclase 2C (GUCY2C). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This product is essential for research focused on the role of GUCY2C in various biological processes and disease states.

Cat. No.

AT0453

Anti-LAMP1/CD107a Antibody

Synonyms: SAR-428926 antibody

The Anti-LAMP1/CD107a Antibody (SAR-428926 antibody) is a humanized monoclonal antibody targeting LAMP1/CD107a. This antibody serves as the antibody component of the therapeutic SAR-428926. It is characterized as Human IgG1 kappa and can also be utilized as an isotype control in various experimental setups. This product is designed for research applications, focusing on the study of lysosomal associated membrane protein 1 (LAMP1), which is critical in cellular processes such as autophagy and lysosome stabilization.

Cat. No.

AT0455

CAS No.

204658-47-9

Torapsel

Synonyms: 42-89-glycoprotein; WAY164339; pMT21:PL85

Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein that incorporates elements of immunoglobulin. This biologic is specifically designed for use in experimental studies focused on the prevention of ischemia-reperfusion injury. Torapsel's unique structure and functional properties make it a valuable tool for researchers investigating cellular mechanisms and therapeutic interventions related to tissue damage following restored blood flow after ischemic events.

Cat. No.

AT0456

CAS No.

2611099-93-3

Crefmirlimab

Crefmirlimab is a humanized minibody specifically targeting CD8. This minibody retains the target specificity characteristic of full-length antibodies while lacking immune effector functions, rendering it biologically inert. This feature makes it particularly suitable for detailed studies of CD8 interactions without eliciting an immune response, ideal for controlled experimental setups in immunology and oncology research.

Cat. No.

AT0461

CAS No.

2851870-28-3

Olintatug

Olintatug is a chimeric humanized antibody of the IgG1κ subtype that specifically targets KAAG1. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Cat. No.

AT0473

CAS No.

725735-28-4

Intetumumab

Synonyms: CNTO 95; Anti-Human CD51 Recombinant Antibody

Intetumumab (CNTO 95) is a glycoengineered anti-EGFR monoclonal antibody designed to enhance antibody-dependent cellular cytotoxicity (ADCC). This potent therapeutic tool is specifically utilized in cancer research to investigate the mechanisms of tumor cell inhibition mediated by EGFR targeting.

Cat. No.

AT0474

CAS No.

1610010-60-0

Varisacumab

Synonyms: R 84 (antibody; GNR-011

Varisacumab (R 84) is a monoclonal antibody designed for biochemical research applications. This antibody offers specificity in targeting and studying molecular interactions, making it a valuable tool for a wide range of biochemical investigations.

Cat. No.

AT0481

CAS No.

946415-62-9

Ontuxizumab

Synonyms: MORAb-004

Ontuxizumab (MORAb-004) is a humanized IgG1 kappa monoclonal antibody targeting endosialin (also known as TEM-1 or CD248). This antibody exhibits antitumor properties by specifically binding to endosialin, a protein predominantly expressed in tumor vasculature and certain tumor stromal cells. Ontuxizumab is utilized primarily in cancer research to investigate its therapeutic potential and mechanism of action in tumor inhibition.

Cat. No.

AT0484

CAS No.

2158362-38-8

Neihulizumab

Synonyms: ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab

Neihulizumab (ALTB-168) functions as an agonistic antibody targeting the immune checkpoint receptor CD162, also known as PSGL-1. By binding to this receptor, Neihulizumab effectively mediates the downregulation of activated T-cells. This antibody is primarily utilized in research focusing on steroid-refractory acute graft-versus-host disease (SR-aGVHD), as well as studies related to psoriasis, psoriatic arthritis, and ulcerative colitis. Its unique mechanism and specificity make it a valuable tool in the investigation of immune response modulation in these conditions.

Cat. No.

AT0487

Anti-ALP Antibody

Cat. No.

AT0494

Anti-MMP9 Antibody

The Anti-MMP9 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target MMP9 (Matrix Metallopeptidase 9). This antibody is constructed from a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 144.76 kDa. For isotype control, researchers should use the Human IgG2 kappa, Isotype Control, which serves as an appropriate reference for assessing the specificity and binding characteristics of the Anti-MMP9 Antibody in various experimental setups. This product is suitable for a range of applications in the study of enzyme regulation and tissue remodeling processes.

Cat. No.

AT0499

CAS No.

1417158-65-6

Xentuzumab

Synonyms: BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

Xentuzumab (BI836845) is a recombinant human monoclonal antibody specifically designed to target and neutralize the insulin-like growth factors IGF1 and IGF2. By binding to these ligands, Xentuzumab effectively inhibits their role in promoting cellular growth and proliferation. Additionally, this antibody suppresses the activation of AKT, a critical kinase in the PI3K/AKT signaling pathway, further impeding oncogenic signaling. This dual mechanism of action makes Xentuzumab a valuable tool in research focused on cancer biology, particularly in studies exploring the regulation of growth factor-mediated signal transduction and its impact on cellular behaviors.

Cat. No.

AT0502

Anti-CD1a Antibody (OKT-6)

The Anti-CD1a Antibody (OKT-6) is a chimeric mouse monoclonal antibody of the IgG1 subtype, specifically designed to target human CD1a. For optimal experimental control, it is recommended to use Mouse IgG1 kappa as the isotype control. This product is ideal for research applications requiring precise targeting of the CD1a molecule.

Cat. No.

AT0531

CAS No.

216503-58-1

Mitumomab

Mitumomab is a mouse-derived IgG2b monoclonal antibody with anti-idiotypic properties, designed to mimic the structure of the ganglioside GD3. This antibody is primarily utilized in the study of small-cell lung carcinoma, offering a valuable tool for researchers investigating the pathophysiology and potential therapeutic targets of this aggressive cancer type.

Cat. No.

AT0534

Anti-CTSS/Cathepsin S Antibody (Fsn0503h)

The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized monoclonal antibody specifically targeting CTSS/Cathepsin S, expressed in Chinese Hamster Ovary (CHO) cells. This antibody is comprised of a human IgG1 type heavy chain and a human kappa (huκ) type light chain, and exhibits a predicted molecular weight of 150 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa, Isotype Control. This antibody is essential for research focusing on the role of CTSS/Cathepsin S in various biological processes and diseases.